This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A third view: Digging into the P1/2 results and potential of Relay Therapeutics' FGFR2 inhibitor, RLY-4008, in cholangiocarcinoma.

Ticker(s): RLAY, INCY, Taiho Pharmaceuticals, QED Therapeutics

Who's the expert?

Institution: Zangmeister Cancer Center

  •  Board certified in Oncology and Hematology and is a member of American Society of Clinical Oncology, American Association for Cancer Research, and International Society of Gastrointestinal Oncology.
  • Research focuses on improving patient outcomes using targeted therapies and genomic medicine including clinical research at The Zangmeister Cancer Center.
  • Evaluates and treats all blood and cancer disorder with a special interest in gastrointestinal cancers

Interview Goal
This conversation will be focused on the potential of Relay Therapeutics' FGFR2 inhibitor, RLY-4008, and the results from the ReFocus Phase 1/2 Study of RLY-4008 in cholangiocarcinoma which were presented at ESMO in September of 2022.

Do you want answers to these questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.